Tuesday, April 12, 2022 Daily Archives

German pandemic prep wins for GSK, CureVac, Wacker, and more

by

As part of a pandemic preparedness plan, Germany has struck several deals to secure manufacturing capacity for hundreds-of-millions of doses of mRNA-based vaccines. To support the continued COVID-19 pandemic and to be better prepared for future health crises, Germany has secured messenger RNA (mRNA) vaccine manufacturing capacity across a range of partners. The first deal, announced last week, sees German vaccine maker BioNTech reserve and maintain manufacturing capabilities to produce at least 80 million mRNA-based vaccine doses per year for…

April 12, 2022

Not All cGMP Transfection Reagents Are Made Equal: Pharmaceutical Versus Medical Device cGMP Manufacturing

by

cGMP grade transfection reagents should be produced and formulated following strict guidelines. Some suppliers manufacture transfection reagents according to medical devices cGMP standards which makes the reagents suitable for viral vector manufacturing in the United States but not suitable for direct administration into humans. Those are often labelled as “for research use only and further manufacturing. Not for use in humans or animalsâ€. Others comply to pharmaceuticals cGMP guidelines, making the transfection reagent suitable for viral vector manufacturing as well…

April 12, 2022

Samsung Bio spending $347m to buy land for Biocampus 2

by

CDMO Samsung Biologics has agreed to buy land close to its site in Songdo, Korea for future greenfield projects including capacity expansions. Samsung Biologics has grown over the past decade into one of the largest biologics contract development and manufacturing organization (CDMO), with three operational facilities at its biocampus in Songdo, Incheon boasting a total of 364,000 L of mostly stainless-steel bioreactor capacity. A fourth ‘super plant’ under construction will add a further 256,000 L of capacity, and a future…

April 12, 2022